Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free TORC Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

resTORbio (TORC) Competitors

resTORbio logo
Compare

TORC vs. AVTE, LWAC, SBTX, ELYM, and NLTX

Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Aerovate Therapeutics (AVTE), LightWave Acquisition (LWAC), Silverback Therapeutics (SBTX), Eliem Therapeutics (ELYM), and Neoleukin Therapeutics (NLTX).

How does resTORbio compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and resTORbio (NASDAQ:TORC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

resTORbio's return on equity of -78.12% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
resTORbio N/A -78.12%-71.63%

46.2% of resTORbio shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 11.8% of resTORbio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
resTORbioN/AN/A-$82.74M-$2.41N/A

In the previous week, Aerovate Therapeutics had 1 more articles in the media than resTORbio. MarketBeat recorded 1 mentions for Aerovate Therapeutics and 0 mentions for resTORbio. Aerovate Therapeutics' average media sentiment score of 0.75 beat resTORbio's score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aerovate Therapeutics Positive
resTORbio Neutral

Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, resTORbio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Summary

Aerovate Therapeutics and resTORbio tied by winning 5 of the 10 factors compared between the two stocks.

How does resTORbio compare to LightWave Acquisition?

resTORbio (NASDAQ:TORC) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

46.2% of resTORbio shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LightWave Acquisition's return on equity of 0.00% beat resTORbio's return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
LightWave Acquisition N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41N/A
LightWave AcquisitionN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
resTORbio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, resTORbio's average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.

Company Overall Sentiment
resTORbio Neutral
LightWave Acquisition Neutral

Summary

LightWave Acquisition beats resTORbio on 3 of the 5 factors compared between the two stocks.

How does resTORbio compare to Silverback Therapeutics?

resTORbio (NASDAQ:TORC) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

46.2% of resTORbio shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

resTORbio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Silverback Therapeutics' return on equity of -29.62% beat resTORbio's return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
Silverback Therapeutics N/A -29.62%-28.20%

Silverback Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41N/A
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A

In the previous week, resTORbio's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company Overall Sentiment
resTORbio Neutral
Silverback Therapeutics Neutral

Summary

Silverback Therapeutics beats resTORbio on 5 of the 8 factors compared between the two stocks.

How does resTORbio compare to Eliem Therapeutics?

resTORbio (NASDAQ:TORC) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

resTORbio has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41N/A
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A

Eliem Therapeutics' return on equity of -47.03% beat resTORbio's return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
Eliem Therapeutics N/A -47.03%-45.97%

46.2% of resTORbio shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Eliem Therapeutics had 1 more articles in the media than resTORbio. MarketBeat recorded 1 mentions for Eliem Therapeutics and 0 mentions for resTORbio. Eliem Therapeutics' average media sentiment score of 0.67 beat resTORbio's score of 0.00 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
resTORbio Neutral
Eliem Therapeutics Positive

Summary

Eliem Therapeutics beats resTORbio on 7 of the 10 factors compared between the two stocks.

How does resTORbio compare to Neoleukin Therapeutics?

resTORbio (NASDAQ:TORC) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

resTORbio has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
resTORbioN/AN/A-$82.74M-$2.41N/A
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A

Neoleukin Therapeutics' return on equity of -37.22% beat resTORbio's return on equity.

Company Net Margins Return on Equity Return on Assets
resTORbioN/A -78.12% -71.63%
Neoleukin Therapeutics N/A -37.22%-30.91%

46.2% of resTORbio shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Neoleukin Therapeutics had 1 more articles in the media than resTORbio. MarketBeat recorded 1 mentions for Neoleukin Therapeutics and 0 mentions for resTORbio. resTORbio's average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.

Company Overall Sentiment
resTORbio Neutral
Neoleukin Therapeutics Neutral

Summary

Neoleukin Therapeutics beats resTORbio on 5 of the 9 factors compared between the two stocks.

Get resTORbio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TORC vs. The Competition

Export
MetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$238.77M$883.41M$6.25B$11.76B
Dividend YieldN/A4.84%2.74%5.26%
P/E Ratio-3.621.7129.2527.07
Price / SalesN/A119.23504.6973.43
Price / CashN/A20.0743.3053.90
Price / Book2.927.609.676.69
Net Income-$82.74M-$4.80M$3.55B$332.64M

resTORbio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TORC
resTORbio
N/A$6.55
+1.9%		N/A+877.6%$238.77MN/AN/AN/A
AVTE
Aerovate Therapeutics
N/A$24.40
+9.3%		N/A+96.5%$707.23MN/AN/A20
LWAC
LightWave Acquisition
N/A$10.18
0.0%		N/AN/A$306.16MN/AN/AN/A
SBTX
Silverback Therapeutics
N/A$8.26
+5.4%		N/A-40.8%$297.84MN/AN/A83
ELYM
Eliem Therapeutics
N/A$9.26
-2.5%		N/A+663.0%$275.50MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TORC) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Did you miss The Dark AI Summit?
Over 55,000 people attended Jeff Brown's Dark AI Summit, where he revealed a private AI company he believes ho...
Brownstone Research | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel